Khurram Nasir et al. JACC 2015;66:

Slides:

Advertisements

Similar presentations

Nonsense Mutations in PCSK9 and Cardiovascular Risk Factors among 3363 Black Participants in the Study Jonathan C.Cohen, et al, N Engl J Med 2006;354:

Advertisements

Introduction to: 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults BLUF: -Shift from.

The use of ezetimibe boosts the rate of the ESC/EAS LDL-C target achievement together with the rate of LDL-C lowering response suggested by the ACC/AHA.

2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults: A Report of the American College.

10 Points to Remember on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in AdultsTreatment of Blood Cholesterol to Reduce.

Coronary Artery Calcium

2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults Scott W. Rypkema, M.D.

Date of download: 5/28/2016 Copyright © The American College of Cardiology. All rights reserved. From: 2013 ACC/AHA Guideline on the Treatment of Blood.

Date of download: 5/29/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Further Insight Into the Cardiovascular Risk Calculator:

Date of download: 5/29/2016 Copyright © The American College of Cardiology. All rights reserved. From: Primary Prevention With Statins: ACC/AHA Risk-Based.

Date of download: 6/22/2016 Copyright © The American College of Cardiology. All rights reserved. From: Accuracy of Statin Assignment Using the 2013 AHA/ACC.

Date of download: 6/29/2016 Copyright © The American College of Cardiology. All rights reserved. From: A Test in Context: High-Sensitivity C-Reactive Protein.

Date of download: 6/29/2016 Copyright © The American College of Cardiology. All rights reserved. From: The metabolic syndrome, diabetes, and subclinicalatherosclerosis.

Date of download: 9/18/2016 Copyright © The American College of Cardiology. All rights reserved. From: Implications of Coronary Artery Calcium Testing.

Date of download: 9/18/2016 Copyright © The American College of Cardiology. All rights reserved. From: Next Steps in Primary Prevention of Coronary Heart.

Diabetes is not an homogeneous risk: The role of coronary calcium score in the reclassification of cardiovascular risk in diabetic patients JOSEPH SHEMESH.

Date of download: 11/12/2016 Copyright © The American College of Cardiology. All rights reserved. From: 2016 ACC Expert Consensus Decision Pathway on the.

Stepwise approach to assessing cardiac patient risk for noncardiac surgery. (Reproduced, with permission, from Fleisher LA et al. ACC/AHA 2007 Guidelines.

Stepwise approach to assessing cardiac patient risk for noncardiac surgery. (Reproduced, with permission, from Fleisher LA et al. ACC/AHA 2007 Guidelines.

Major recommendation for statin therapy for ASCVD prevention

2013 ACC/AHA cholesterol treatment guidelines

Nat. Rev. Cardiol. doi: /nrcardio

Safi U. Khan MD; John Pamula MD

Cholesterol practice questions

From: Treatment of Blood Cholesterol to Reduce Risk for Atherosclerotic Cardiovascular DiseaseGrand Rounds Discussion From the Beth Israel Deaconess Medical.

(From Stone NJ, Robinson JG, Lichtenstein AH, et al

Copyright © 2012 American Medical Association. All rights reserved.

American College of Cardiology/American Heart Association (ACC/AHA) Class I Guidelines for the Treatment of Cholesterol to Reduce Atherosclerotic Cardiovascular.

A Summary and Critical Assessment of the 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Disease.

Errors in Electronic Health Record–Based Data Query of Statin Prescriptions in Patients With Coronary Artery Disease in a Large, Academic, Multispecialty.

Introduction to: 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults BLUF: -Shift from.

Circ Cardiovasc Qual Outcomes

Introduction to: 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults BLUF: -Shift from.

Zhi-hui Hou et al. JIMG 2012;5:

Use of the Coronary Artery Calcium Score in Discussion of Initiation of Statin Therapy in Primary Prevention Erin D. Michos, MD, MHS, Michael J. Blaha,

Neil J. Stone et al. JACC 2014;63:

A Summary and Critical Assessment of the 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Disease.

Sunjoo Boo, RN, PhD, Erika Sivarajan Froelicher, RN, PhD, FAAN

Cardiovascular Disease Prevention in Men with Vascular Erectile Dysfunction: The View of the Preventive Cardiologist Nishant P. Shah, MD, Miguel Cainzos-Achirica,

Martin W. Schoen, MD, MPH, Joanne Salas, MPH, Jeffrey F

Introduction to: 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults BLUF: -Shift from.

Patrizio Lancellotti et al. JIMG 2016;9:

Dean J. Kereiakes et al. JACC 2017;70:

Martin Bødtker Mortensen, and Erling Falk JACC 2018;71:85-94

Johannes Steiner et al. JACC 2017;70:

Introduction to: 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults BLUF: -Shift from.

Primary and Secondary Prevention of Cardiovascular Disease

Cardiovascular disease in women with HIV-1 infection

Rational Order of Laboratory Tests in Cardiovascular Diseases

2013 ACC/AHA cholesterol treatment guidelines

Contemporary Evidence-Based Guidelines

Introduction to: 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults BLUF: -Shift from.

Baseline Characteristics

Kaplan–Meier estimates of the incidence of first heart failure hospitalization during follow-up according to the statin category among patients with type.

Nicolaj C. Hansson et al. JACC 2016;68:

New Lipid-Lowering Guidelines

Characteristics of included studies

Preventative Cardiology

Jeffrey L. Anderson et al. JACC 2007;50:e1-e157

Glenn N. Levine et al. JACC 2011;58:e44-e122

Intensive Lowering of Low-Density Lipoprotein Cholesterol Levels for Primary Prevention of Coronary Artery Disease Dean G. Karalis, MD Mayo Clinic Proceedings

Potential effect of guidelines on ASCVD prevention in the CGPS*

Alan Rozanski et al. JIMG 2017;10:

Requested Information by CMS Team During April 30th Hearing

Steven R. Steinhubl, and Eric J. Topol JACC 2015;66:

Amir A. Mahabadi et al. JIMG 2017;10:

James O. Mudd et al. JACC 2007;50:

James H O'Keefe, Jr et al. JACC 2004;43:

Heat map of microRNA microarray expression from the four groups of patients. Heat map of microRNA microarray expression from the four groups of patients.

The cumulative incidence curve demonstrated that patients with a sub-optimal LDL-C response to statin therapy were associated with a higher risk of CVD.

Presentation transcript:

Khurram Nasir et al. JACC 2015;66:1657-1668 Impact of the Absence of CAC in Reclassifying Risk Below the Threshold for Statin Consideration Suggested by ACC/AHA Cholesterol Management Guidelines Across the Spectrum of Estimated 10-Year ASCVD Risk Score (Nondiabetic Patients With LDL-C of 70 to 189 mg/dl) The absence of CAC reclassifies risk below the threshold for statin consideration in 40% (956 of 2,411) of statin candidates (>5% ASCVD estimate), and in 49% (956 of 1,970) of those with ASCVD risk between 5% and 20%. ACC/AHA = American College of Cardiology/American Heart Association; ASCVD = atherosclerotic cardiovascular disease; CAC = coronary artery calcium; LDL-C = low-density lipoprotein cholesterol. Khurram Nasir et al. JACC 2015;66:1657-1668 American College of Cardiology Foundation